TY - JOUR
T1 - The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis.
AU - Pattison, H
AU - Daniels, Jane
AU - Kai, J
AU - Gupta, Janesh
PY - 2011/11/1
Y1 - 2011/11/1
N2 - Please cite this paper as: Pattison H, Daniels J, Kai J, Gupta JK. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. BJOG 2011;118:1528-1531. Menorrhagia, or heavy menstrual bleeding (HMB), is a common gynaecological condition. As the aim of treatment is to improve women's wellbeing and quality of life (QoL), it is necessary to have effective ways to measure this. This study investigated the reliability and validity of the menorrhagia multi-attribute scale (MMAS), a menorrhagia-specific QoL instrument. Participants (n = 431) completed the MMAS and a battery of other tests as part of the baseline assessment of the ECLIPSE (Effectiveness and Cost-effectiveness of Levonorgestrel-containing Intrauterine system in Primary care against Standard trEatment for menorrhagia) trial. Analyses of their responses suggest that the MMAS has good measurement properties and is therefore an appropriate condition-specific instrument to measure the outcome of treatment for HMB.
AB - Please cite this paper as: Pattison H, Daniels J, Kai J, Gupta JK. The measurement properties of the menorrhagia multi-attribute quality-of-life scale: a psychometric analysis. BJOG 2011;118:1528-1531. Menorrhagia, or heavy menstrual bleeding (HMB), is a common gynaecological condition. As the aim of treatment is to improve women's wellbeing and quality of life (QoL), it is necessary to have effective ways to measure this. This study investigated the reliability and validity of the menorrhagia multi-attribute scale (MMAS), a menorrhagia-specific QoL instrument. Participants (n = 431) completed the MMAS and a battery of other tests as part of the baseline assessment of the ECLIPSE (Effectiveness and Cost-effectiveness of Levonorgestrel-containing Intrauterine system in Primary care against Standard trEatment for menorrhagia) trial. Analyses of their responses suggest that the MMAS has good measurement properties and is therefore an appropriate condition-specific instrument to measure the outcome of treatment for HMB.
U2 - 10.1111/j.1471-0528.2011.03057.x
DO - 10.1111/j.1471-0528.2011.03057.x
M3 - Article
C2 - 21790952
SN - 1471-0528
VL - 118
SP - 1528
EP - 1531
JO - BJOG
JF - BJOG
IS - 12
ER -